THE ROLE OF AAC-DESIGNATED CLADRIBINE ORAL TABLETS IN RE-ESTABLISHING MS SERVICES AFTER COVID-19
In this promotional webinar we will explore the challenges in getting patients back on to DMT treatment during the COVID-19 pandemic and look at the role of cladribine tablets in appropriate patients to support continuation of MS services during the UK’s COVID-19 response. Each panelist will deliver a short presentation, followed by a facilitated Q&A on the issues discussed.
INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – LONDON PERSPECTIVE
Dr Heather Wilson, Consultant Neurologist, National Hospital for Neurology and Neurosurgery, London
INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – NOTTINGHAM UNIVERSITY HOSPITAL PERSPECTIVE
Dr Nikos Evangelou, Consultant Neurologist & Associate Clinical Professor, Nottingham University Hospital
INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – SOUTH WEST PERSPECTIVE
Professor Jeremy Hobart, Consultant Neurologist, Plymouth Hospitals NHS Trust
CHAIRED BY DR CHARLIE DAVIE, CONSULTANT NEUROLOGIST, UCLPARTNERS
This standalone promotional webinar is aimed at individuals within AHSNs who have an interest in MS services and the MS clinical community, including MS neurologists, MS nurses and pharmacists.
Sign up for this event